Forecast

Buy	3
Hold	3
Sell	0

News Go to news feed

EVOTEC seeks new chief scientific officer – Cord Dohrmann to leave at end of September

Cord Dohrmann will step down as chief scientific officer and member of the executive board of EVOTEC on 30 September; the decision was mutual. Dohrmann has held the position since 2010. A search for his successor is underway; the EVOTEC share was slightly firmer in XETRA trading. » More on finanzen.net
Evotec leads SDAX after optimistic conference outlook

The Evotec share rose to €3.098 and led the SDAX higher, driven by an optimistic outlook at a conference. CFO Claire Hinshelwood said business indicators were developing “in the right direction” and are likely to translate into future revenues. The cost-saving programme Horizon is running as planned and the pipeline of deals is robust. » More on finanzen.net
Evotec reaches Pentagon milestone with Phase‑I clinical study, stock remains weak

Just‑Evotec Biologics launches a Phase‑I study for the orthopox antibody cocktail JST‑018 under a U.S. Department of Defense program; together with a previous contract the potential order volume is up to USD 123.9 million. The project confirms the functionality of Evotec’s continuous‑manufacturing platform through production of clinical material and strengthens the high‑margin biologics division. Chart‑wise, Evotec’s share remains in an intact downtrend and is trading near its 52‑week low, so investors will still need patience and risk tolerance until operational successes are reflected in the group’s financials. » More on finanzen.net

Financials

In the last quarter, Evotec had revenue of €143.48m and net profit of -€46.65m

(EUR)	June 2026	YoY
Revenue	143.48m	16.21%
Gross profit	-1.58m	118.38%
Net profit	-46.65m	7.29%
EBITDA	-26.69m	66.60%

Fundamentals

Metric	Value
Market capitalization	€538.11m
Number of shares	177.19m
52-week high/low	€7.29 - €2.71
Dividends	No
Beta	1.08
P/E ratio	-2.73
PEG ratio	0.03
P/B ratio	0.81
P/S ratio	0.75

Company profile

Evotec SE ist als Wirkstoffforschungs- und -entwicklungspartner für die Pharma- und Biotechnologiebranche weltweit tätig. Das Unternehmen entwickelt pharmazeutische Produkte in verschiedenen therapeutischen Bereichen wie Diabetes und Diabetes-Komplikationen, Fibrose, Infektionskrankheiten, ZNS-Krankheiten, Onkologie, Schmerz und Entzündung, Immunologie, seltene Krankheiten, Atemwegserkrankungen und Frauengesundheit. Das Unternehmen hat Kooperationsvereinbarungen mit Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd, Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics und Takeda Pharmaceuticals. Das Unternehmen war früher unter dem Namen Evotec AG bekannt und änderte im April 2019 seinen Namen in Evotec SE. Die Evotec SE wurde 1993 gegründet und hat ihren Hauptsitz in Hamburg, Deutschland.